A new study identified protein targets and drug candidates, including opportunities to repurpose existing drugs. Six key ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential drug targets for the treatment of multiple sclerosis. The study may pave the ...

Scientists are testing two new molecules that may repair myelin in MS, shifting the focus from slowing attacks to true nerve ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said ...

Jan 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's (TEVA ...

Sanofi (SNY) announced on Wednesday that the U.S. FDA issued a complete response letter regarding its marketing application for tolebrutinib, rejecting the drug for patients with multiple sclerosis, ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...